Final Glance: Biotechnology companies
AP - Fri Aug 01, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Pharmacyclics Incurs Q2 Loss, Revenues Up on Imbruvica Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 4:10PM CDT
Pharmacyclics (PCYC) reported better than expected revenues on strong Imbruvica sales.
Endo International Beats on Q2 Earnings & Sales, Guidance Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 2:36PM CDT
Endo (ENDP) reported higher-than-expected earnings and revenues in the quarter.
Midday Glance: Biotechnology companies
AP - Fri Aug 01, 12:35PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Pharmacyclics Q2 Earnings Get Mixed Reception
at Investor's Business Daily - Fri Aug 01, 11:35AM CDT
Biotech Pharmacyclics (PCYC) was seesawing on the stock market today after its Q2 sales beat consensus late Thursday, but the company declined to update its guidance. Pharmacyclics' sales more than doubled over the year-earlier quarter to $113...
Incyte Posts Wider-than-Expected Q2 Loss, Raises Sales View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 10:17AM CDT
Incyte Corporation (INCY) reported a loss of 22 cents per share in the second quarter of 2014, significantly wider than the Zacks Consensus Estimate of a loss of 9 cents.
Early Glance: Biotechnology companies
AP - Fri Aug 01, 10:08AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Celgene Up 18.4% Since SmarTrend Uptrend Call (CELG)
Comtex SmarTrend(R) - Fri Aug 01, 9:15AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 3 months, Celgene has returned 18.39% as of today's recent price of $87.53.
BioMarin Q2 Loss Narrower than Expected, Revenue Guidance Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 4:00PM CDT
BioMarin (BMRN) reported a narrower-than-expected loss aided by higher revenues.
United Therapeutics (UTHR) Up on Q2 Earnings & Revenue Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 12:20PM CDT
Lower costs and higher revenues helped United Therapeutics (UTHR) deliver better-than-expected earnings.
Bayer Earnings Grow Marginally Y/Y, New Products Encourage - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:41AM CDT
Bayer's (BAYRY) newly launched products performed well in the quarter.
Stock Market News for July 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:10AM CDT
Benchmarks ended Wednesday’s choppy trading session little changed after the Federal Reserve offered a mixed view on the economy
Biotech Earnings Put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - ZACKS - Thu Jul 31, 9:01AM CDT
Following solid results from Amgen, among others, these biotech ETFs could be ones to watch.
Biotech Valuations Are Low Not Stretched. Here's Why.
at The Street - Thu Jul 31, 7:35AM CDT
If biotech companies can assuage concerns about long-term growth, multiples might expand.
'Mad Money' Lightning Round: Stay With Thermo Fisher Scientific
at The Street - Thu Jul 31, 5:00AM CDT
Cramer isn't crazy about Nimble Storage but thinks Pitney Bowes stock can go higher.
Jim Cramer's 'Mad Money' Recap: Thinking 5 Steps Ahead and Being Wrong
at The Street - Wed Jul 30, 6:55PM CDT
There are five groups of investors fighting over the direction of the markets, making for a confusing jumble of cross-currents, Cramer says.